Navigation Links
Orchid Cellmark Reports Improved First Quarter 2009 Financial Results
Date:5/7/2009

on, intellectual property of others, patent protection, litigation, the timing of release of federal and state funds, the timing and amount of contracts put up for bid, and Orchid Cellmark's ability to successfully offer its services directly to U.K. police forces. These risks and other additional factors affecting these forward-looking statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.

Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press release.

(See attached Financial Tables)

                      Orchid Cellmark Inc. and Subsidiaries
                  Condensed Consolidated Statements of Operations
                    Three months ended March 31, 2009 and 2008
                       (In thousands, except pe
'/>"/>
SOURCE Orchid Cellmark Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Orchid Cellmark to Announce First Quarter 2009 Financial Results on May 7, 2009
2. Orchid Cellmark Reports Fourth Quarter and Full Year 2008 Financial Results
3. Orchid Cellmark to Announce Fourth Quarter and Year-End 2008 Financial Results on March 16, 2009
4. Orchid Cellmark Reports Third Quarter 2008 Financial Results
5. Orchid Cellmark Reports Second Quarter 2008 Financial Results
6. Orchid Cellmark To Announce Second Quarter 2008 Financial Results on July 31, 2008
7. Orchid Cellmark Reports First Quarter 2008 Financial Results
8. Orchid Cellmark to Open a New Forensic Facility in the United Kingdom to Meet Increasing Demand for Its Services
9. Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results
10. Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
11. Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Meadows, Ill. (PRWEB) April 21, 2015 ... to the late cosmetic dermatologist Fredric S. Brandt, M.D., ... , Dr. Brandt, an ASDS member since 1982, died ... home. The funds are designed to provide opportunities for ... the field of cosmetic dermatology that Dr. Brandt held ...
(Date:4/21/2015)... BAR, CALIF. (PRWEB) April 21, 2015 ... leading provider of enterprise Time and Attendance / ... 33rd Annual Congress from the American Payroll Association ... Partner Conference. , The APA has been the ... Congress brings workshops, networking opportunities, and recertification credits. ...
(Date:4/21/2015)... The PracticeMatch Career Fair will take ... at the William and Ida Friday Center at UNC-Chapel Hill, ... 50 hospitals, clinics and groups with career opportunities will be ... Attendees will enjoy free hors d’oeuvres and raffle prize drawings. ... says “Chapel Hill is an ideal location to hold ...
(Date:4/21/2015)... DC (PRWEB) April 21, 2015 ... announce the launch of Medicare-Medicaid Dual Eligibles Database, ... focuses on care provided to the more than ... who account for more than $300 billion in ... researchers – the same team that also creates ...
(Date:4/21/2015)... eSight is the only technology in the world that ... Tuesday, May 5th, Low Vision Specialists of Maryland and ... an unveiling and demonstration of the technology at 8:30 a.m ... will be the first ophthalmic practice in Maryland to offer ... will be available on the day of the unveiling. , ...
Breaking Medicine News(10 mins):Health News:ASDS honors the legacy of Dr. Fredric Brandt 2Health News:ASDS honors the legacy of Dr. Fredric Brandt 3Health News:ASDS honors the legacy of Dr. Fredric Brandt 4Health News:NOVAtime Participates in 2015 APA Congress and NetSuite SuiteWorld Conferences in May 2Health News:NOVAtime Participates in 2015 APA Congress and NetSuite SuiteWorld Conferences in May 3Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 3Health News:New AIS Database Tracks All Programs, Plans Serving the Dual-Eligible Community 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 3
... earliest intervention may reduce risk , , MONDAY, March 30 (HealthDay ... six months of life may be more prone to obesity ... our preventive methods when children are much younger," said study ... of weeks of life, we can start guiding parents about ...
... Billion Each Year According to the Better Sleep CouncilDALLAS, March ... Unfortunately, sleep is usually one of the first things people ... In a turbulent economy, nearly 30 percent of Americans ... according to a 2009 Sleep in America poll by the ...
... preference for procedures that offer improved aesthetic results will ... to Millennium Research GroupWALTHAM, Mass., March 30 According ... Markets for Dental Implants 2009 report, although ... growth in the short term, the US dental implant ...
... Enhancements maximize and automate physician practice reporting, collections and ... March 30 iMedica Corporation ... for physician practices, today announced the availability of its ... 2009 is the latest version of iMedica,s award-winning Electronic ...
... NUVA ), a medical device company focused ... the spine, announced today that due to the successful ... the transfer of the processing of Osteocel Plus from ... own exclusive supply chain. Since the May 2008 announcement ...
... Two-Year Study- Conference Call Scheduled for Today at ... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... (Behavioral modification and Lorcaserin for Overweight and Obesity ... the safety and efficacy of lorcaserin for weight ...
Cached Medicine News:Health News:Rapid Infant Weight Gain Linked to Childhood Obesity 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 3Health News:Dental Implant Market to Exceed $1 Billion by 2013 Despite Current Economic Slowdown 2Health News:iMedica Corporation Announces the Release of Patient Relationship Manager 2009 2Health News:iMedica Corporation Announces the Release of Patient Relationship Manager 2009 3Health News:Long Term Supply of Osteocel(R) Plus Solidified Without Ownership of Processing Facility 2Health News:Long Term Supply of Osteocel(R) Plus Solidified Without Ownership of Processing Facility 3Health News:Long Term Supply of Osteocel(R) Plus Solidified Without Ownership of Processing Facility 4Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 2Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 3Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 4Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 5Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 6Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 7Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 8Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 9Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 10Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 11
(Date:4/21/2015)... LOS ANGELES , April 21, 2015 /PRNewswire/ ... quality plan administrator and the exclusive worldwide sales, ... GenStrip™ 50, the FDA-cleared Green Alternative Strip, specifically ... & Johnson,s LifeScan OneTouch Ultra family of glucose ... diabetic use, announced today that Johnson & Johnson/Lifescan ...
(Date:4/21/2015)... , April 21, 2015  The American Association ... Food and Drug Administration that the agency,s regulatory ... the last 25 years to protect the public ... medicines. AAHP, the industry,s trade association, was joined ... homeopathic medicines to engage in productive discussions with ...
(Date:4/21/2015)... , April 21, 2015  Edico Genome today ... solutions with Intel,s Xeon processors to accelerate next ... will enable completion of primary and secondary NGS ... decreasing costs, streamlining data analysis in the cloud ... of big data sets, such as analysis of ...
Breaking Medicine Technology:Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case 2Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case 3Speakers at FDA Hearing Praise Success of Homeopathic Regulatory Framework 2Edico Genome Collaborates with Intel to Overcome Big Data Bottleneck in Next-Generation Sequencing 2Edico Genome Collaborates with Intel to Overcome Big Data Bottleneck in Next-Generation Sequencing 3
... Also Announces Deal for Vaccine Delivery System, ... Corporation announced today that the Company's HIV ... primate model.,Mucosal IgA antibodies are considered a ... HIV. The data were presented by,Sylvain Fleury, ...
... Patients Prefer Orapred ODT Over Liquid, ALPHARETTA, ... announced today survey results showing that,children prefer ... over liquid steroids.(1) , The results of ... children (n=973), showed that 89% (n=870) of ...
Cached Medicine Technology:Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 2Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 3Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 4Orapred ODT Tastes Good 2Orapred ODT Tastes Good 3
LigaSure system generator, bipolar only. Designed to permanently seal vessels and tissue bundles....
Sabre 180 is a powerful niche generator....
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: